The lipogenic LXR-SREBF1 signaling pathway controls cancer cell DNA repair and apoptosis and is a vulnerable point of malignant tumors for cancer therapy
- 6 March 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cell Death & Differentiation
- Vol. 27 (8), 2433-2450
- https://doi.org/10.1038/s41418-020-0514-3
Abstract
Cancer cells are defective in DNA repair, so they experience increased DNA strand breaks, genome instability, gene mutagenesis, and tumorigenicity; however, multiple classic DNA repair genes and pathways are strongly activated in malignant tumor cells to compensate for the DNA repair deficiency and gain an apoptosis resistance. The mechanisms underlying this phenomenon in cancer are unclear. We speculate that a key DNA repair gene or signaling pathway in cancer has not yet been recognized. Here, we show that the lipogenic liver X receptor (LXR)-sterol response element binding factor-1 (SREBF1) axis controls the transcription of a key DNA repair gene polynucleotide kinase/phosphatase (PNKP), thereby governing cancer cell DNA repair and apoptosis. Notably, the PNKP levels were significantly reduced in 95% of human pancreatic cancer (PC) patients, particularly deep reduction for sixfold in all of the advanced-stage PC cases. PNKP is also deficient in three other types of cancer that we examined. In addition, the expression of LXRs and SREBF1 was significantly reduced in the tumor tissues from human PC patients compared with the adjacent normal tissues. The newly identified LXR-SREBF1-PNKP signaling pathway is deficient in PC, and the defect in the pathway contributes to the DNA repair deficiency in the cancer. Strikingly, further diminution of the vulnerable LXR-SREBF1-PNKP signaling pathway using a small molecule triptonide, a new LXR antagonist identified in this investigation, at a concentration of 8 nM robustly activated tumor-suppressor p53 and readily elevated cancer cell DNA strand breaks over an apoptotic threshold, and selectively induced PC cell apoptosis, resulting in almost complete elimination of tumors in xenograft mice without obvious complications. Our findings provide new insight into DNA repair and apoptosis in cancer, and offer a new platform for developing novel anticancer therapeutics.Keywords
Funding Information
- The National Natural Science Foundation of China
This publication has 67 references indexed in Scilit:
- Liver X Receptors Inhibit Proliferation of Human Colorectal Cancer Cells and Growth of Intestinal Tumors in MiceGastroenterology, 2013
- Liver X Receptors Protect from Development of Prostatic Intra-Epithelial Neoplasia in MicePLoS Genetics, 2013
- Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunityMolecular Oncology, 2012
- Impact of PNKP mutations associated with microcephaly, seizures and developmental delay on enzyme activity and DNA strand break repairNucleic Acids Research, 2012
- Synthesis and Evaluation of Diarylthiazole Derivatives That Inhibit Activation of Sterol Regulatory Element-Binding ProteinsJournal of Medicinal Chemistry, 2011
- Complex Oncogenic Translocations with Gene Amplification Are Initiated by Specific DNA Breaks in LymphocytesCancer Research, 2009
- Hepatitis B virus X protein induces lipogenic transcription factor SREBP1 and fatty acid synthase through the activation of nuclear receptor LXRαBiochemical Journal, 2008
- Antiproliferative Effect of Liver X Receptor Agonists on LNCaP Human Prostate Cancer CellsCancer Research, 2004
- T0901317 is a dual LXR/FXR agonistMolecular Genetics and Metabolism, 2004
- Polyunsaturated Fatty Acids Suppress Sterol Regulatory Element-binding Protein 1c Promoter Activity by Inhibition of Liver X Receptor (LXR) Binding to LXR Response ElementsPublished by Elsevier BV ,2002